In Some European Clinical Cytogenetic Labs, Arrays Have Become Primary Sample-Analysis Tool

Several European lab directors interviewed by BioArray News said the switch occurred over the past year as a result of falling array prices and because lab techs have become more confident in their ability to interpret results as they have gained more experience with the technology.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.